theHeart.org: Lipid and Metabolic news related to heart conditions.

Lipid/Metabolic

Lipid Insights From AHA 2009

Nov 20, 2009 15:32 EST

Dr. Michael Davidson, a nationally recognized cardiologist and clinical lipidologist, will lead a targeted discussion focusing on the interpretation and application of results presented at this year's AHA meeting. Joining him will be a distinguished faculty panel, including: Dr. Christie Ballantyne, Director of the Center for Cardiovascular Disease Prevention at Baylor College of Medicine; Dr. Vera Bittner, Section Head of Preventive Cardiology at the University of Alabama at Birmingham and President of the National Lipid Association; and Dr. Roger Blumenthal, Director of the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease.

Lipid/Metabolic

On the Road to New Lipid Guidelines

28 COMMENTS - Jun 30, 2009 00:59 EDT

Join Drs. Blumenthal and Ridker as they inform our community about upcoming consensus guidelines which will address this current medical debate, as well as the limitations of existing treatments as they formulate their management strategies.

Lipid/Metabolic

hsCRP - How Will Recent Statin Trials Impact CV Risk Assessment?

21 COMMENTS - Dec 19, 2008 11:00 EST

How will the results of JUPITER expand the universe of cardiovascular risk evaluation? Join Drs Ballantyne, Ridker, and Chapman as they discuss this important biomarker study and its implication for clinical practice.

Lipid/Metabolic

Combination Therapy for the Management of Mixed Dyslipidemia

28 COMMENTS - Dec 18, 2008 15:20 EST

What's the latest on reducing residual risk? Read Dr Polsani's overview of the latest clinical trial data on management strategies for mixed dyslipidemia. Then watch Drs Davidson, Plutzky, Wierzbicki, Ballantyne and Nesto as they each give their take including reactions to data released at AHA 2008.

Lipid/Metabolic

Early Detection of CV Risk: The When and How of Biomarker Tests

8 COMMENTS - Dec 17, 2008 11:00 EST

Join our panel of experts, Drs Ridker, Blumenthal, Ballantyne, and Wilson as they discuss the pathophysiology of inflammation as it relates to the development and progression of CVD and how systemic inflammation biomarkers can be used as surrogate endpoints in clinical trials of therapeutic agents.

Lipid/Metabolic

Dyslipidemia and type 2 diabetes: Translating clinical trial data into improving outcomes

14 COMMENTS - Jun 9, 2008 17:47 EDT

Join Drs Frank Sacks, Peter Jones and Theodore Mazzone as they discuss how the results of new clinical trials will affect the treatment of mixed dyslipidemia and reduce cardiovascular risk in patients with type 2 diabetes.

Lipid/Metabolic

CB1 blockade and type 2 diabetes: The SERENADE study

Jan 25, 2007 13:56 EST

Diabetes affects approximately 194 million individuals worldwide. A large majority of these cases is due to type 2 diabetes and is linked to patients being overweight or obese. Reducing weight and controlling glucose in diabetic patients is important in order to minimize the risk of heart disease and other disabling complications. The SERENADE study examined the benefit of using CB1 blockade in type 2 diabetes to tackle cardiometabolic risk.

Cardiometabolic risk

Knowledge of cardiometabolic risk: How do you measure up?

2 COMMENTS - Dec 20, 2006 10:32 EST

Despite lifestyle changes and current drug therapies, obesity and cardiometabolic risk remain persistent treatment challenges. Are you up to date on emerging pharmacological options? Test your knowledge against your peers regarding the use of CB1 blockade.

Lipid/Metabolic

Treating patients with CB1 blockade: The United Kingdom experience

4 COMMENTS - Dec 19, 2006 11:51 EST

With 23% of the population worldwide now obese, the risks of developing CV disease and type 2 diabetes are escalating. Lifestyle changes and current pharmacological interventions are having limited success. Explore case studies of CB1 blockade as part of the treatment regimen in countries where approved.

Lipid/Metabolic

CB1 blockade: Who's the ideal patient?

Nov 23, 2006 11:50 EST

In recent years, healthcare providers have become more aware of the risks of CVD and diabetes associated with abdominal obesity. What if the patient is not obese but simply overweight? How do we best assess the risk? What do we do when lifestyle changes and conventional pharmacological treatments are not successful? Evidence supports that cannabinoid-1 receptor (CB1) blockade therapy could be a promising alternative. If CB1 blockade becomes available in the United States, who will be the ideal candidate? Join our faculty as they explore these thought-provoking questions.

Lipid/Metabolic

Tackling abdominal obesity and cardiovascular risk around the world

Oct 12, 2006 10:32 EDT

Obesity is a growing epidemic around the world, with over 300 million obese individuals worldwide. The presence of abdominal obesity, which is easily determined by measuring waist circumference, has been identified as a contributing factor to cardiovascular risk. Ethnic and gender differences related to this disorder exist around the globe. This program will highlight the magnitude of the problem, explore gender and ethnic differences, and discuss strategies for managing the care of obese patients. Get the Canadian perspective on abdominal obesity and cardiovascular risk from Drs Abramson, Genest, and Lonn.

Lipid/Metabolic

Highlights from EASD 2006: Targeting CV risk in dysglycemic patients

Oct 6, 2006 15:26 EDT

The incidence of diabetes is projected to rise from 171 million in 2000 to 366 million in 2030. One contributing factor to the escalating incidence is the global epidemic of abdominal obesity. Modern lifestyles and dietary habits are contributing to an increase in diabetes with a consequent rise in inter-related cardiometabolic risk factors. This program will review recent research findings related to the relationship between cardiometabolic risk factors and diabetes, with an emphasis on future trends for management of the patient with dysglycemia

Cardiometabolic risk

CB blockade with rimonabant

2 COMMENTS - Sep 5, 2006 11:45 EDT

Abdominal obesity is known to increase the risk of comorbidities such as insulin resistance, type 2 diabetes, dyslipidemia and hypertension, and has been linked to cardiovascular risk independently of body mass index. This health threat is largely due to an excess of intra-abdominal adipose tissue. CB1 receptor blockade has been shown to improve cardiometabolic risk factors both directly and indirectly by reducing intra-abdominal adiposity. This symposium will review the risks associated with abdominal obesity as well as data surrounding rimonabant, the first CB1 receptor antagonist.

Cardiometabolic risk

Knowledge of cardiometabolic risk: How do you measure up?

2 COMMENTS - Jul 24, 2006 09:35 EDT

Cardiometabolic risk

ADA 2006 Spotlight — The enigma of prediabetes: Impact on cardiovascular risk

1 COMMENT - Jun 20, 2006 16:20 EDT

According to the American Diabetes Association, 41 million people in the US aged 40-74 years have prediabetes and many will develop diabetes within 10 years. While glucose elevations may be below the threshold of diabetes, the patient is at risk for heart disease, retinopathy and kidney dysfunction. This program will highlight the ongoing debate defining prediabetes, the significance of early recognition of dysglycemia, and current research toward the reduction of CV risk in dysglycemic patients.

Cardiometabolic risk

Cardiometabolic risk in women: An equal opportunity killer

1 COMMENT - Jun 1, 2006 16:30 EDT

CVD remains the number one killer of both men and women. Sex disparities are well documented with some speculation that suboptimal preventive care and lack of awareness of personal CVD risk may contribute to poor outcomes in women. This program highlights the findings of a recently published large study which focused on screening of cardiometabolic risk in women.

Cardiometabolic risk

Knowledge of cardiometabolic risk: How do you measure up?

4 COMMENTS - May 12, 2006 12:00 EDT

Increasing awareness of the relationship between specific cardiometabolic risk factors and CVD remains at the forefront of medical education. Are you familiar with each risk factor and how it impacts your patients' health? Are you informed regarding the most recent research, treatment strategies, and potential new treatments on the horizon? It is highly important to measure your knowledge in this arena so you can optimize preventive measures in your patients. Take this opportunity to evaluate your knowledge and see how you measure up in comparison to your peers.

Cardiometabolic risk

Expert commentary: Evaluating the shape of our world: The IDEA survey

Mar 31, 2006 15:05 EST

Cardiovascular disease (CVD) remains the major cause of mortality worldwide and is responsible for approximately 17 million deaths per year. This figure is expected to rise to 24 million by 2030. Recent findings support that abdominal obesity is a much better predictor of CVD than weight or body mass index, but this information is not available in all countries. The IDEA survey addresses the assessment of abdominal obesity in 63 countries in over 177 000 patients presenting to primary care.

Cardiometabolic risk

ACC 2006 Focus on: Exploration of cardiometabolic risk

Mar 22, 2006 16:13 EST

Cardiometabolic risk combines classical risk factors (smoking, elevated cholesterol, hypertension, and diabetes) with emerging markers such as intra-abdominal obesity and insulin resistance. At the American College of Cardiology 2006 Scientific Sessions many presentations focused on assessing cardiovascular risk. This program will highlight several of those presentations and provide new insights related to ethnic/gender differences, new serum markers, economic impact, and strategies for assessing and treating patients at risk for cardiovascular disease.

Cardiometabolic risk

Looking beyond lipemic and glycemic control: Exploring CV risk reduction with statins, glitazones, and fenofibrates

1 COMMENT - Dec 6, 2005 14:02 EST

Recent debates and recommendations support the lower is better hypothesis regarding LDL-C levels. Diabetic patients with an increased risk of coronary events will most likely benefit from such aggressive lowering. Glitazones and fenofibrates have demonstrated great benefit in such patients. Dr Chris Cannon will discuss recent research findings related to these topics.

	Yes
	No